Correlation between adenosine receptor SNPs polymorphism and therapeutic effect of caffeine in the treatment of apnea of prematurity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015609

Enrollment

Unknown

Registered

2018-04-11

Start date

2018-06-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea of prematurity

Interventions

standard dosage group:caffeine treatment with loading dose of 20mg/kg, and maintenance dose of 5-10mg/kg

high dosage group:In case of standard regimen not works, the maintenance was increased to 20mg/kg.dose

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. preterm with gestation age of equal to and lower than 34weeks; 2. recurrent episodes of apnoea=4 times in 24h.

Exclusion criteria

Exclusion criteria: Any of the following condition were excluded, including: anemia, severe infections, severe asphyxia, grade III-IV intracranial hemorrhage, neonatal convulsion, obstructive apnea, severe gastroesophageal reflux, arrhythmia and mechanical ventilation has been used when patient is assessed(including nCPAP, NIPPV and NHFOV noninvasive ventilation).

Design outcomes

Primary

Measure	Time frame
SNPs genotypes of three groups of patients;Recurrent episodes of bronchopulmonary dysplasia(BPD);Prognosis of nervous system;	—

Secondary

Measure	Time frame
Duration of apnea;Duration of mechanical ventilation;Hospitalization days;The hospital outcomes;	—

Countries

China

Contacts

Public ContactJianhui Wang

Children's Hospital of Chongqing Medical University

wangjh805@126.com+86 13678428167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026